Swedish cohort links semaglutide to 21% lower psychiatric hospitalization in bipolar disorder
Liraglutide and dulaglutide showed no such association, suggesting any effect may not extend across the GLP-1 class.
PR
By Priya Raman · Science Reporter
Sep 14 11:15 ETSource: Medical Dialogues
The wire
- 01Researchers analyzed nationwide Swedish data on nearly 15,000 people with bipolar disorder prescribed GLP-1 drugs from 2009 to 2024; semaglutide periods carried 21% lower hospitalization risk.
- 02Findings in Acta Psychiatrica Scandinavica bear on prescribing for patients who have both bipolar disorder and metabolic disease.
- 03Observational within-person design cannot establish causation; the lead author says a randomized controlled trial is needed.
From the source
Read at medicaldialogues.inOzempic and Wegovy may have an unexpected mental health benefit, finds study
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used to treat diabetes and support weight loss, may also have benefits for mental health, particularly among people with bipolar disorder, according to new research from Griffith University.